AstraZeneca’s TAGRISSO demonstrated strong OS benefit in ADAURA Phase III trial for adjuvant…
AstraZeneca's (AZN) TAGRISSO demonstrated strong OS benefit in ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
Positive high-level results from the ADAURA Phase III trial showed…